Diabetes is one of the most pressing chronic disease challenges of the modern era, affecting hundreds of millions of people globally and straining healthcare systems across every region. What is changing is not the scale of the disease — that has grown steadily for decades — but the tools available to manage, monitor, and treat it. Artificial intelligence is now embedded across the full spectrum of diabetes care, from the continuous glucose monitors worn on the arm to the computational platforms designing next-generation drug molecules.
The commercial momentum behind this transformation is substantial. The market for AI in diabetes management is valued at $1.2 billion in 2025 and is projected to grow at a CAGR of 30.2% during the forecast period from 2022 to 2027, reaching $2.1 billion by 2027. Investment signals reinforce the market data: a $2.75 billion global licensing deal between Eli Lilly and Insilico Medicine in early 2026, a $1 billion AI lab launched by Lilly and NVIDIA, and venture funding rounds ranging from $19 million to $85 million flowing into AI-driven diabetes startups between 2024 and 2025 together demonstrate how seriously both industry and capital markets are taking this transition. Six technology areas are defining where this transformation is concentrated and where it is heading.
Generative AI platforms analyze vast biological and genomic datasets to design novel drug molecules, identify new therapeutic targets, and optimize compound structures for efficacy, safety, and manufacturability. Traditional drug discovery is time-consuming, costly, and characterized by high failure rates — problems that generative AI addresses directly by automating target identification and molecule design with greater speed and precision than conventional laboratory workflows.
• ImmunoPrecise Antibodies developed AI-designed GLP-1 therapies for type 2 diabetes and obesity using its proprietary LensAI platform, representing a fully AI-generated drug candidate advancing toward clinical use.
• Insilico Medicine and Eli Lilly are collaborating using generative AI to accelerate target discovery and develop AI-designed drug candidates, culminating in a licensing deal valued at up to $2.75 billion.
• Novo Nordisk partnered with OpenAI in 2026 to apply advanced AI across drug discovery and R&D, analyzing complex datasets to identify new candidates for diabetes and obesity.
• Dexcom's GenAI platform provides personalized weekly insights for CGM users, linking lifestyle factors such as diet, exercise, and sleep to glucose trends.
• Eli Lilly's TuneLab AI and machine learning platform gives biotech companies access to drug discovery models trained on more than $1 billion worth of proprietary research data.
AI algorithms embedded in or connected to continuous glucose monitors analyze real-time glucose data streams to detect patterns, predict glucose fluctuations, and deliver personalized alerts and insights. This shifts diabetes management from a reactive posture — responding to high or low glucose after the fact — to a proactive one, where interventions happen before dangerous episodes occur.
• Dexcom G7 and Abbott FreeStyle Libre analyze glucose trends and deliver real-time alerts that prompt proactive intervention before hypoglycemic or hyperglycemic events develop.
• Roche's Accu-Chek SmartGuide CGM, which received CE Mark approval in 2024, predicts glucose trends and hypoglycemia risk for adults with type 1 and type 2 diabetes on flexible insulin therapy.
• MicroTech Medical's AiDEX X and LinX CGM systems in China monitor glucose levels and deliver predictive alerts integrated with insulin pumps for a semi-automated management workflow.
• IBM and Roche co-developed an AI-enabled diabetes solution using CGM data and IBM watsonx to predict glucose levels up to two hours ahead.
• Abbott's Libre Assist uses AI and CGM data to guide real-time food decisions for people with diabetes, personalizing dietary guidance at the moment it is most relevant.
• Zydus Lifesciences' Diasens and GlucoLive CGM systems, launched in March 2026, provide real-time glucose tracking with integrated AI-driven digital health support.
Closed-loop systems integrate CGM sensors with AI-driven insulin pumps to automatically analyze glucose data and adjust insulin dosing in real time without requiring the patient to intervene manually. This convergence of sensor technology, AI algorithms, and delivery hardware substantially reduces hypoglycemia risk and the daily cognitive burden on patients, representing one of the most clinically meaningful advances in diabetes device technology.
• Tandem Diabetes Care's Control-IQ system continuously analyzes CGM data to adjust basal insulin delivery and deliver correction boluses, adapting to individual diet, exercise, and metabolic patterns in North America.
• Beta Bionics' bionic pancreas system, backed by $60 million in Series E funding in 2024, automates insulin delivery using adaptive algorithms designed to operate without user input.
• Insulet Corporation's Omnipod 5 received FDA-cleared algorithm enhancements in December 2025 enabling a lower glucose target of 100 mg/dL and improved automated insulin adjustments for type 1 diabetes.
• Medtronic's MiniMed 780G with SmartGuard algorithm is integrated with Abbott CGM technology for AI-driven interoperable insulin delivery across devices from different manufacturers.
• Luna Diabetes is developing the world's smallest insulin patch pump incorporating a closed-loop dosing algorithm, having closed a $23.6 million Series A round in August 2025.
AI systems analyze retinal images to automatically detect early signs of diabetic retinopathy — the leading cause of preventable blindness in people with diabetes — without requiring an ophthalmologist at the point of care. Automated screening can reach rural clinics, community health settings, and underserved populations where specialists are unavailable, enabling early intervention that preserves vision and reduces downstream treatment costs.
• Eyenuk's EyeArt AI system is deployed across major diabetes centers in Germany, including the Heart and Diabetes Center North Rhine-Westphalia and Tübingen University Hospital, replacing or supplementing specialist review for routine screening.
• India's MadhuNetr DR-AI project, led by the Rajasthan state government, uses AI-powered retinal imaging to screen rural communities for diabetic retinopathy, addressing a significant care gap in one of the countries with the highest diabetes burden globally.
• Avant and Ainnova's Vision AI technology conducts early retinal screenings in underserved communities in Mexico, extending specialist-level diagnostic capability without requiring specialist infrastructure.
• Remote deployment of AI retinal screening platforms enables proactive identification of complications before patients become symptomatic, reducing the need for costly late-stage interventions.
AI digital twin platforms create individualized computational models of a patient's metabolic system, drawing on data from wearables, CGMs, and health records to simulate and optimize personalized treatment strategies. Rather than applying population-level guidelines, digital twins calibrate care to each individual's biology and behavior, making precision medicine operationally feasible at scale.
• Twin Health's AI digital twin platform supports diabetes and weight management across enterprise clients, scaling personalized metabolic care to large employer populations; the company raised $53 million in 2025 to accelerate this model.
• Ultrahuman's platform pairs CGM data with AI algorithms to deliver personalized diet, activity, and lifestyle insights for metabolic fitness, serving a growing consumer-facing market across Asia-Pacific.
• RadarFit uses Microsoft Azure AI to power personalized wellness programs promoting healthier lifestyles for diabetes prevention among users in Brazil.
• The MELISSA Project in Europe is testing an AI-powered digital platform for personalized insulin therapy optimization across multi-country clinical studies, representing a regulator-engaged institutional application of individualized care.
Dedicated AI supercomputers and high-performance computing systems built for biomedical and pharmaceutical research enable analysis of massive biological datasets at a scale that general-purpose infrastructure cannot match. In diabetes research, this layer underpins everything from target identification and molecule design to clinical trial optimization and disease diagnostics.
• The Novo Nordisk Foundation's Gefion AI supercomputer in Denmark became operational in October 2024, purpose-built to accelerate drug discovery and disease diagnostics including for diabetes.
• Eli Lilly and NVIDIA launched a $1 billion co-innovation AI lab in January 2026, deploying generative AI, machine learning, and large-scale simulations for target identification, molecule design, and clinical trial design.
• The AITHYRA institute, established by the Boehringer Ingelheim Foundation at the Austrian Academy of Sciences with approximately $160 million in committed funding, focuses on biomedical AI research including diabetes.
Within the AI in diabetes management landscape, growth is concentrated across glucose monitoring, insulin delivery, and drug discovery — the three subsegments where AI integration is most mature and commercially validated. Continuous glucose monitoring and closed-loop insulin delivery are driving hardware and software revenue, while generative AI in drug discovery is attracting the largest single investment transactions.
Regionally, North America leads, supported by FDA regulatory frameworks including January 2025 guidance on AI and machine learning-enabled medical devices and the FDA's Digital Health Center of Excellence. Europe is a strong second, backed by the EU AI Act, MDR and IVDR regulatory structures, and a $1.5 billion EU deep tech investment targeting AI healthcare innovation. Asia-Pacific represents a high-growth opportunity driven by high diabetes prevalence, government-led screening programs such as India's MadhuNetr DR-AI project, and consumer AI health platforms expanding in China. The Middle East and Africa are emerging, with Roche launching an AI-enabled predictive CGM solution in the region in 2026. Latin America is at an earlier stage but active, with startups in Mexico and Brazil deploying AI-driven retinal screening and personalized wellness programs to underserved communities.
The integration of AI across diabetes care is no longer a horizon technology — it is a present reality deployed in clinical settings, enterprise health programs, and government screening initiatives on multiple continents. The six technology areas covered here — generative AI for drug discovery, AI-enabled continuous glucose monitoring, closed-loop automated insulin delivery, AI-powered retinal imaging, AI digital twin platforms for metabolic health, and AI supercomputing infrastructure for biomedical research — are collectively restructuring how diabetes is detected, monitored, managed, and treated.
Over the forecast period through 2027, the industry will face genuine challenges: fragmented data infrastructure limiting AI model accuracy across populations, care access gaps in low- and middle-income countries, and the ethical and data governance requirements that accompany medical AI deployment. But the scale of investment — from billion-dollar pharma collaborations to tens of millions flowing into device startups — reflects broad conviction that AI's productivity gains in diabetes care are durable, and that the underlying demand, driven by a global disease burden showing no sign of declining, will sustain commercial returns across the value chain.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.